Ana M. Gamo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana M. Gamo has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Arnab K. Chatterjee
Calibr at Scripps Research, The Scripps Research Institute, La Jolla, CA 92037, USA
2 shared publications- Sean B. Joseph
Calibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA
2 shared publications - Alan Chu
Calibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute
1 shared publication - Ana María Celentano
Departamento de Microbiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires C1113AAD, Argentina
1 shared publication Ashley K. Woods
California Institute for Biomedical Research, 11119 North Torrey Pines Road, La Jolla, CA 92037, USA
1 shared publicationBrent Benish
California Institute for Biomedical Research, 11119 North Torrey Pines Road, La Jolla, CA 92037, USA
1 shared publication
Latest Publications
- Open Access
- 16 June 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (12) , 3983-3993
A small molecule UPR modulator for diabetes identified by high throughput screening
- 16 June 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (12) , 3983-3993
Open AccessA small molecule UPR modulator for diabetes identified by high throughput screening
- Top Cited Papers
- 21 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6506) , 993-999
Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic
Targeting STING for cancer therapy: Activation of the STING (stimulator of interferon genes) protein by cyclic dinucleotide metabolites plays a critical role in antitumor immunity. The development of synthetic STING agonists is therefore being pursued as a strategy for cancer therapy, but the inherent instability of dinucleotides has limited current efforts. Pan et al. and Chin et al. identified stable STING agonists that act in a “closed” conformation similar to the natural STING ligand, cyclic guanosine monophosphate–adenosine monophosphate (see the Perspective by Gajewski and Higgs). The small molecules can be given orally—an advantage over previously developed STING agonists, which required intratumoral administration. After oral or systemic administration in mice, the agonists activated STING and diverse immune cell types to promote antitumor immunity. These studies represent progress toward clinically viable STING agonists for cancer immunotherapy. Science , this issue p. eaba6098 , p. 993 ; see also p. 921
- 21 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6506) , 993-999
Top Cited PapersAntitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic
Targeting STING for cancer therapy: Activation of the STING (stimulator of interferon genes) protein by cyclic dinucleotide metabolites plays a critical role in antitumor immunity. The development of synthetic STING agonists is therefore being pursued as a strategy for cancer therapy, but the inherent instability of dinucleotides has limited current efforts. Pan et al. and Chin et al. identified stable STING agonists that act in a “closed” conformation similar to the natural STING ligand, cyclic guanosine monophosphate–adenosine monophosphate (see the Perspective by Gajewski and Higgs). The small molecules can be given orally—an advantage over previously developed STING agonists, which required intratumoral administration. After oral or systemic administration in mice, the agonists activated STING and diverse immune cell types to promote antitumor immunity. These studies represent progress toward clinically viable STING agonists for cancer immunotherapy. Science , this issue p. eaba6098 , p. 993 ; see also p. 921
- Open Access
- 9 February 2018
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 12 (2) , e0006267
Unique pharmacological properties of serotoninergic G-protein coupled receptors from cestodes
Cestodes are a diverse group of parasites, some of them being agents of neglected diseases. In cestodes, little is known about the functional properties of G protein coupled receptors (GPCRs) which have proved to be highly druggable targets in other organisms. Notably, serotonergic G-protein coupled receptors (5-HT GPCRs) play major roles in key functions like movement, development and reproduction in parasites. Three 5-HT GPCRs from Echinococcus granulosus and Mesocestoides corti were cloned, sequenced, bioinformatically analyzed and functionally characterized. Multiple sequence alignment with other GPCRs showed the presence of seven transmembrane segments and conserved motifs but interesting differences were also observed. Phylogenetic analysis grouped these new sequences within the 5-HT7 clade of GPCRs. Molecular modeling showed a striking resemblance in the spatial localization of key residues with their mammalian counterparts. Expression analysis using available RNAseq data showed that both E. granulosus sequences are expressed in larval and adult stages. Localization studies performed in E. granulosus larvae with a fluorescent probe produced a punctiform pattern concentrated in suckers. E. granulosus and M. corti larvae showed an increase in motility in response to serotonin. Heterologous expression revealed elevated levels of cAMP production in response to 5-HT and two of the GPCRs showed extremely high sensitivity to 5-HT (picomolar range). While each of these GPCRs was activated by 5-HT, they exhibit distinct pharmacological properties (5-HT sensitivity, differential responsiveness to ligands). These data provide the first functional report of GPCRs in parasitic cestodes. The serotoninergic GPCRs characterized here may represent novel druggable targets for antiparasitic intervention. Cestode parasites are flatworms with the ability to parasitize almost every vertebrate species. Several of these parasites are etiological agents of neglected diseases prioritized by WHO, such as hydatid disease, or hydatidosis, a zoonosis caused by species of the genus Echinococcus that affects millions of people worldwide. Due to the scarcity of anthelmintic drugs available and the emergence of resistant parasites, the discovery of new anthelmintic drugs is mandatory. Neuromuscular function has been the target of commonly used drugs against parasitic diseases to impact movement, parasite development and reproduction. Here we describe three new proteins, some of them highly expressed in cestodes which could be relevant for motility. Using different approaches, the three proteins were identified as G protein coupled receptors for serotonin, an important neurotransmitter and a known modulator of cestode motility. These new receptors exhibit unique characteristics including a particular sensitivity to serotonin as well as a distinctive pharmacology, which will assist their targeting for chemotherapeutic intervention.
- 9 February 2018
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 12 (2) , e0006267
Open AccessUnique pharmacological properties of serotoninergic G-protein coupled receptors from cestodes
Cestodes are a diverse group of parasites, some of them being agents of neglected diseases. In cestodes, little is known about the functional properties of G protein coupled receptors (GPCRs) which have proved to be highly druggable targets in other organisms. Notably, serotonergic G-protein coupled receptors (5-HT GPCRs) play major roles in key functions like movement, development and reproduction in parasites. Three 5-HT GPCRs from Echinococcus granulosus and Mesocestoides corti were cloned, sequenced, bioinformatically analyzed and functionally characterized. Multiple sequence alignment with other GPCRs showed the presence of seven transmembrane segments and conserved motifs but interesting differences were also observed. Phylogenetic analysis grouped these new sequences within the 5-HT7 clade of GPCRs. Molecular modeling showed a striking resemblance in the spatial localization of key residues with their mammalian counterparts. Expression analysis using available RNAseq data showed that both E. granulosus sequences are expressed in larval and adult stages. Localization studies performed in E. granulosus larvae with a fluorescent probe produced a punctiform pattern concentrated in suckers. E. granulosus and M. corti larvae showed an increase in motility in response to serotonin. Heterologous expression revealed elevated levels of cAMP production in response to 5-HT and two of the GPCRs showed extremely high sensitivity to 5-HT (picomolar range). While each of these GPCRs was activated by 5-HT, they exhibit distinct pharmacological properties (5-HT sensitivity, differential responsiveness to ligands). These data provide the first functional report of GPCRs in parasitic cestodes. The serotoninergic GPCRs characterized here may represent novel druggable targets for antiparasitic intervention. Cestode parasites are flatworms with the ability to parasitize almost every vertebrate species. Several of these parasites are etiological agents of neglected diseases prioritized by WHO, such as hydatid disease, or hydatidosis, a zoonosis caused by species of the genus Echinococcus that affects millions of people worldwide. Due to the scarcity of anthelmintic drugs available and the emergence of resistant parasites, the discovery of new anthelmintic drugs is mandatory. Neuromuscular function has been the target of commonly used drugs against parasitic diseases to impact movement, parasite development and reproduction. Here we describe three new proteins, some of them highly expressed in cestodes which could be relevant for motility. Using different approaches, the three proteins were identified as G protein coupled receptors for serotonin, an important neurotransmitter and a known modulator of cestode motility. These new receptors exhibit unique characteristics including a particular sensitivity to serotonin as well as a distinctive pharmacology, which will assist their targeting for chemotherapeutic intervention.